Human Erythropoietin-alpha Recombinant

/, CD markers, Recombinant Human Cytokines/Human Erythropoietin-alpha Recombinant

Human Erythropoietin-alpha Recombinant


accession P01588

Source Optimized DNA sequence encoding Human EPO mature chain was expressed in CHO cells.
Molecular weight Nativehuman Erythropoietin-alpha is generated by the proteolytic removal of the signal peptide and propeptide, the molecule has a calculated molecular mass of approximately kDa. Recombinant EPO-a is a glycosylated disulfide-linked homodimeric protein consisting of amino acid residue subunits, and migrates as an approximately kDa protein under reducing conditions in SDS-PAGE.
Purity >98%, as determined by SDS-PAGE and HPLC
Biological Activity Activity was determined by the dose-dependent proliferation assay using a factor-dependent human erythroleukemic cell line TF-1 and was found to be.8x105 IU/mg.
Endotoxin Endotoxin content was assayed using a LAL gel clot method. Endotoxin level was found to be less than.1 ng/µg(1EU/µg).
Presentation Recombinant Erythropoietin alpha was lyophilized from a.2 μm filtered PBS solution pH.
Reconstitution A quick spin of the vial followed by reconstitution in distilled water to a concentration not less than.1 mg/mL. This solution can then be diluted into other buffers
Storage The lyophilized protein is stable for at least years from date of receipt at -20° C. Upon reconstitution, this cytokine can be stored in working aliquots at° -° C for one month, or at -20° C for six months, with a carrier protein without detectable loss of activity. Avoid repeated freeze/thaw cycles.
Usage This cytokine product is for research purposes only.It may not be used for therapeutics or diagnostic purposes.

Interactor P19235 EPOR_HUMAN
Biological Process Erythrocyte-maturation
Molecular function Hormone


Effects of overexpression of Bmi1 on HSCs in vitro.

3 U/ml human EPO
  • Single CD34-LSK cells were sorted into 96-well microtiter plates containing the SF-O3 medium supplemented with 10% FBS and multiple cytokines (10 ng/ml SCF, 10 ng/ml TPO, 10 ng/ml IL-3, and 3 u/ml EPO) and allowed to form colonies.

Colony-forming assay

  • The effects of SNS-032, perifosine, or combination on the leukemia colony formation (CFU-L) in methylcellulose medium were examined using leukemic colony assay as previously described [3) in 600 μL of methylcellulose solution were incubated in the presence of the agents or an equivalent amount of medium at 37°C in a humidified atmosphere with 5% CO2.
  • Primary leukemic cells were cultured in methylcellulose medium containing recombinant human (rh) stem cell factor (SCF), granulocyte macrophage-colony-stimulating factor (GM-CSF), and interleukin 3 (IL-3) at 2 × 104 cells/dish.
  • After 7 days, CFU-Ls that contain >40 cells were scored manually under a light microscope .
  • For colony assay of human normal bone marrow cells, 3 U/mL rh erythropoietin , 50 ng/mL rhSCF, 30 ng/mL rhGM-CSF, and 10 ng/mL rhIL-3 were added to the methylcellulose medium.
  • The colonies were counted under a microscope on day 12 of culture.

Colony forming analysis

  • celltype'>Leukemic cell lines, MNCs from the patients with, or healthy controls were infected with or without the indicated viruses (50 MOI) and seeded in triplicate in a mixture containing 1.35% methylcellulose in medium'>Iscove's medium'>modified medium'>Dulbecco's medium (IMDM;) supplemented with 20% fetal bovine serum and10−4 M 2-Mercaptoethanol .
  • For colony assay of bone marrow cells, 3 U/mL recombinant human (rh) erythropoietin, 50 ng/mL rh stem cell factor, 30 ng/mL rh granulocyte macrophage–colony-stimulating factor, and 10 ng/mL rh interleukin-3 were added to the methylcellulose medium.
  • The colonies were evaluated under a microscope on day 12 of culture.
  • In contrast, leukemic cell lines were seeded in cytokine-free mixture as described previously [